(At the request of the Taskforce Vaccination - End of May 2021)
Together with the Federal Agency for Medicines and Health products (FAMHP) and the Taskforce Vaccination, KCE did a rapid adaption of the European Medicines Agency (EMA) risk-benefit model for thrombocytopenia syndrome (TTS) after vaccination for Vaxzevria™ to the Johnson & Johnson vaccine. We reused the EU estimates on hospitalisation, ICU and death, provided by EMA, for calculating the possible benefits of vaccination with the Johnson & Johnson vaccine. These possible benefits were then compared to the possible risk on thrombocytopenia syndrome (TTS) after vaccination with the Johnson & Johnson vaccine.
Download the document: Risk benefit in context for TTS events applied to the Johnson & Johnson vaccine (270.25 KB) "pdf"
